For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Agouron Pharmaceuticals, Inc.

Calculating rank

USPTO Granted Patents = 174

% Expired Patents = 42.0

CIPO Patents = 1

Trademarks = 2

Forward Citations = 2,199

Loading Chart...

Loading Chart...

330 inventors (with patents filed for the assignee):

Siegfried Heinz Reich (36 out of 50 patents)

Michael D Varney (33 out of 33 patents)

Cynthia Louise Palmer (26 out of 38 patents)

4. John Howard Tatlock (20 out of 30 patents)

5. Steven Lee Bender (19 out of 26 patents)

6. Stephen Evan Webber (17 out of 54 patents)

7. William H Romines (17 out of 17 patents)

8. Vincent J Kalish (16 out of 16 patents)

9. Peter Scott Dragovich (14 out of 55 patents)

10. Michael J Rodriguez (14 out of 35 patents)

11. Robert Steven Kania (12 out of 40 patents)

12. Thomas Jay Prins (12 out of 13 patents)

13. Michael J Melnick (12 out of 13 patents)

14. Ru Zhou (11 out of 16 patents)

15. Theodore Otto Johnson, Jr (11 out of 13 patents)

Core Competencies:

Protein Kinase Inhibitors

Pyrrolopyrazoles

Indazole Compounds

HIV Protease Inhibitors

VEGF-R Inhibitors

Antibodies

Polymorphs

Neoplastic Agents

RNA-Dependent RNA Polymerase

GNRH Agents

Thienopyridines

Metalloproteinase Inhibitors

174 patents: Sort by Forward Citations

1. 8785632 - Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors (2014-07-22),

2. 8530652 - Pyrrolopyrazoles, potent kinase inhibitors (2013-09-10),

3. 8067591 - Pyrrolopyrazole, potent kinase inhibitors (2011-11-29),

4. 7928226 - Salts and polymorphs of a VEGF-R inhibitor (2011-04-19),

5. 7928214 - P-cadherin antibodies (2011-04-19),

6. 7923457 - Quinoline derivatives (2011-04-12),

7. 7858643 - Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors (2010-12-28),

8. 7807159 - Antibodies to myostatin (2010-10-05),

9. 7465842 - Enantioselective biotransformation for preparation of protein tyrosine kinase inhibitor intermediates (2008-12-16),

10. 7462713 - Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy (2008-12-09),

11. 7462634 - N-(pyridin-2-yl)-sulfonamide derivatives (2008-12-09),

12. 7452537 - P-cadherin antibodies (2008-11-18),

13. 7429578 - Tricyclic inhibitors of poly(ADP-ribose) polymerases (2008-09-30),

14. 7381824 - Quinoline derivatives (2008-06-03),

15. 7323562 - Method of preparing poly(ADP-ribose) polymerases inhibitors (2008-01-29),

Company Overview

Agouron Pharmaceuticals, Inc., based in San Diego, CA, specializes in the development of innovative therapeutics, particularly in the realm of protein kinase inhibitors. The company focuses on advanced research in various core technology areas, including pyrrolopyrazoles, indazole compounds, and HIV protease inhibitors. Agouron is dedicated to addressing complex medical challenges through its expertise in neoplastic agents and VEGF-R inhibitors, contributing significantly to the pharmaceutical landscape with its cutting-edge approaches.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

174 Patents

#30 in San Diego, CA

#505 in California

#2,314 in US

#4,775 in the World

San Diego, CA, United States of America

Agouron Pharmaceuticals, Inc.

Forward Citations = 2,199

330 inventors:

Siegfried Heinz Reich (36 out of 50 patents)

Michael D Varney (33 out of 33 patents)

Cynthia Louise Palmer (26 out of 38 patents)

4. John Howard Tatlock (20 out of 30 patents)

5. Steven Lee Bender (19 out of 26 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Agouron Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/agouron-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…